Tianmu Pharmaceutical announced that the controlling shareholder Huilong Huaze holds 29.99% of the company's shares and plans to transfer 24.355,800 shares of the company's unlimited tradable shares through a public solicitation agreement with the transferee, accounting for 20% of the company's total share capital. The current public offering transfer price is not less than 22 yuan/share. If the implementation of this public collection and transfer is completed, the controlling shareholders and actual controllers of the company may change.

Tianmu Pharmaceutical announced that the controlling shareholder Huilong Huaze holds 29.99% of the company's shares and plans to transfer 24.355,800 shares of the company's unlimited tradable shares through a public solicitation agreement with the transferee, accounting for 20% of the company's total share capital. The current public offering transfer price is not less than 22 yuan/share. If the implementation of this public collection and transfer is completed, the controlling shareholders and actual controllers of the company may change.